Targeting ARL2: Potential Therapies for Various Diseases (G402)

Target Name: ARL2

NCBI ID: G402

ARL2

Targeting ARL2: Potential Therapies for Various Diseases

ARL2 (Adenosine Receptor-Llang 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and gastrointestinal tract. It is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

ARL2 is involved in a wide range of physiological processes in the body, including cardiovascular function, neurotransmission, and immune responses. It is also involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Due to its involvement in multiple physiological processes, ARL2 has been identified as a potential drug target. Researchers are exploring the use of small molecules, antibodies, and other therapeutic approaches to target ARL2 and its function in disease.

One approach to targeting ARL2 is through the use of small molecules. Small molecules can be designed to interact with ARL2 and modulate its activity. These small molecules can be used to either activate or inhibit ARL2-mediated signaling pathways.

Another approach to targeting ARL2 is through the use of antibodies. Antibodies are designed to recognize and bind to specific protein targets, including ARL2. By targeting ARL2 with antibodies, researchers can study its function in disease and develop new treatments.

In addition to small molecules and antibodies, researchers are also exploring other therapeutic approaches to target ARL2. These include genetic modifiers, such as RNA interference and gene editing techniques, as well as cellular signaling pathways.

Overall, ARL2 is a protein that is involved in a wide range of physiological processes in the body. Its potential as a drug target makes it an attractive target for researchers to study and develop new treatments for a variety of diseases.

Protein Name: ADP Ribosylation Factor Like GTPase 2

Functions: Small GTP-binding protein which cycles between an inactive GDP-bound and an active GTP-bound form, and the rate of cycling is regulated by guanine nucleotide exchange factors (GEF) and GTPase-activating proteins (GAP). GTP-binding protein that does not act as an allosteric activator of the cholera toxin catalytic subunit. Regulates formation of new microtubules and centrosome integrity. Prevents the TBCD-induced microtubule destruction. Participates in association with TBCD, in the disassembly of the apical junction complexes. Antagonizes the effect of TBCD on epithelial cell detachment and tight and adherens junctions disassembly. Together with ARL2, plays a role in the nuclear translocation, retention and transcriptional activity of STAT3. Component of a regulated secretory pathway involved in Ca(2+)-dependent release of acetylcholine. Required for normal progress through the cell cycle (PubMed:10831612, PubMed:16525022, PubMed:18234692, PubMed:18588884, PubMed:20740604). Also regulates mitochondrial integrity and function (PubMed:30945270)

The "ARL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets